GLP-1 Patient Support Market Set to Hit $2.85 Billion by 2036, Driven by Onboarding Demand
The market for GLP-1 patient support services is growing fast. Fact.MR now pegs it at $545 million in 2026….
-
-
Can Diabetes and Weight-Loss Drugs Help People with Rheumatoid Arthritis?
About 1.5 million people in the United States live with rheumatoid arthritis. This condition causes ongoing joint swelling, severe…
-
Novo Nordisk Price Target Rises to $80 as Oral Wegovy Surpasses 3 Million Prescriptions
Novo Nordisk received an upgraded price target of $80, while market analysts assigned the stock a Modest Buy rating….
-
Taking Wegovy at Night? Why Timing Can Make or Break Your Results
Weight loss meds like GLP-1s have changed the game for so many people. For a long time, if you…
-
Semaglutide Sustains Reduced Calorie Intake Beyond One Year
Even when people start feeling hungry again, semaglutide helps them eat fewer calories for over a year. A study…
-
Could Weight-Loss Drugs Be Curing Our Alcohol Cravings?
It turns out that semaglutide, the active ingredient in popular GLP-1 drugs like Wegovy and Ozempic, does more than…
-
Oral Semaglutide & Levothyroxine: Key Facts
Oral semaglutide (often prescribed as Rybelsus) has made a big difference in how we manage weight loss and diabetes….
-
Market Competitors Reshape Obesity Pharmacotherapy
Novo Nordisk is way ahead in the race for weight-loss pills. The company rolled out its pill version of…
-
Smart Snacking Strategies for Patients on GLP-1 Receptor Agonist Therapy
GLP-1 receptor agonists have changed the way doctors treat obesity and type 2 diabetes. Drugs like semaglutide and tirzepatide…
-
Stopping GLP-1 Drugs May Raise Mental Health Risks in Type 2 Diabetes Patients
New research shows that people who stop taking GLP-1 receptor agonist drugs may face a higher risk of mental…
